Long-term glycaemic improvement after addition of metformin to insulin in insulin-treated obese type 2 diabetes patients

Diabetes, Obesity and Metabolism

Volumn 3, Issue 6, 2001, Pages 428-434

  Hermann, L S ^a,b   Kalen J ^b   Katzman, P ^b   Lager, I ^b   Nilsson, A ^b   Norrhamn, O ^b   Sartor, G ^b   Ugander, L ^b  

^a Swedish Network for Pharmacoepidemiology   (Sweden)

^b Department of Internal Medicine ^*  (France)

Author keywords

Combination therapy; Insulin; Metformin; Type 2 diabetes

Indexed keywords

C PEPTIDE; CYANOCOBALAMIN; FIBRINOGEN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; ANOREXIA; ARTICLE; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; EPIGASTRIC PAIN; FEMALE; FLATULENCE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RANDOMIZED CONTROLLED TRIAL; SWEATING; TASTE DISORDER; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0035663674     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-1326.2001.00160.x     Document Type: Article

References (25)

1. A desktop guide to type 2 diabetes mellitus
2. Rationale for the use of insulin therapy alone as the pharmacological treatment of type 2 diabetes
3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
4. The use of insulin alone and in combination with oral agents in type 2 diabetes
5. Efficacy of insulin and sulfonylurea combination therapy in type 2 diabetes: A metaanalysis of the randomized placebo-controlled trials
6. Clinical pharmacology of biguanides
7. Metformin for obese, insulin-treated diabetic patients: Improvement in glycaemic control and reduction of metabolic risk factors
8. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control
9. 1c by a new liquid-chromatographic assay: Methodology, clinical utility, and relation to glucose tolerance evaluated
10. Combination therapy with insulin and metformin
11. Advantages of adding metformin to multiple dose insulin therapy in type 2 diabetes
12. Effects of metformin in patients with poorly controlled insulin-treated type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled trial
13. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus
14. Comparison of bed-time insulin regimens in patients with type 2 diabetes mellitus: A randomized controlled trial
15. Metformin versus gliclazide in combination with daily NPH insulin in poorly controlled type 2 diabetic patients: 1-2-year follow-up data
16. Triple therapy of metformin, sulfonylurea, and insulin in type II diabetic patients
17. Metformin: A review of its metabolic effects
18. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
19. Evaluation of optimal therapy in type 2 diabetic patients insufficiently treated with sulfonylureas: The Austrian insulin intervention study
20. Efficacy of bedtime NPH insulin alone, as compared to combination with metformin and/or glipizide in NIDDM patients with secondary failure to oral hypoglycemic agents
21. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients
22. Metformin improved insulin resistance in type I, insulin-dependent, diabetic patients
23. Membrane physiology as a basis for the cellular effects of metformin in insulin resistance and diabetes
24. A risk-benefit assessment of metformin in type 2 diabetes mellitus
25. Basic aspects and clinical uses